Clinical Trials Logo

Parkinson Disease clinical trials

View clinical trials related to Parkinson Disease.

Filter by:

NCT ID: NCT00758368 Withdrawn - Parkinson's Disease Clinical Trials

Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease

Start date: March 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the effects of apomorphine, given by two different methods, to determine how best to manage dyskinesias.

NCT ID: NCT00640952 Withdrawn - Parkinson's Disease Clinical Trials

Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease

Start date: August 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to determine how many patients with Parkinson's disease have compulsive behaviors, and what types of behaviors they have. This study will also determine if acamprosate can be used to treat compulsive behaviors in Parkinson's disease patients.

NCT ID: NCT00608231 Withdrawn - Parkinson's Disease Clinical Trials

Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation

Start date: January 2008
Phase: Phase 2/Phase 3
Study type: Interventional

To test the hypothesis that sedation induced by Dexmedetomidine at levels appropriate for awake, DBS surgery has no significant effect on electrophysiological parameters of DBS micro-electrode recordings

NCT ID: NCT00601978 Withdrawn - Parkinson's Disease Clinical Trials

Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off

Start date: August 2008
Phase: Phase 4
Study type: Interventional

This study will evaluate the effects of immediate release (IR) carbidopa levodopa versus the effects of immediate-release carbidopa/levodopa on ERP parameters in patients with idiopathic PD.

NCT ID: NCT00584090 Withdrawn - Parkinson's Disease Clinical Trials

Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease

Start date: November 2007
Phase: Phase 4
Study type: Interventional

The primary purpose of this study is to measure the efficacy of solifenacin succinate (VESIcare) on treating urinary incontinence in Parkinson's disease patients. The secondary objective of this study is to examine the effect of solifenacin succinate (VESIcare) on symptoms of PD and the patient's quality of life.

NCT ID: NCT00584025 Withdrawn - Parkinson's Disease Clinical Trials

Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease

Start date: December 2007
Phase: Phase 4
Study type: Interventional

The primary purpose of this study is to characterize the acute anti-dyskinetic properties of intravenous levetiracetam in Parkinson's disease patients who have been optimized on antiparkinsonian medication. The secondary objective is to study the effect of intravenous LEV on additional motor and cognitive symptoms of PD.

NCT ID: NCT00472355 Withdrawn - Parkinson's Disease Clinical Trials

Low Dose Apomorphine and Parkinsonism

Start date: October 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if low doses of apomorphine worsen the motor symptoms of Parkinson's disease.

NCT ID: NCT00451815 Withdrawn - Parkinson's Disease Clinical Trials

BIIB014 Phase 2a Monotherapy

Start date: n/a
Phase: Phase 2
Study type: Interventional

To assess the preliminary safety and tolerability of multiple oral doses of BIIB014 in subjects with early PD.

NCT ID: NCT00451633 Withdrawn - Parkinson's Disease Clinical Trials

The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations

Start date: March 2007
Phase: Phase 2
Study type: Interventional

A randomized, double blind, placebo-controlled study employing a mixed parallel group and fixed sequence cross-over design. Patients will be randomized to one of two treatment groups ('E2007' or 'Placebo') in a 1:1 ratio and receive investigational drug treatment concomitant with their standard individualized anti-Parkinsonian therapy for a total of six weeks. Investigational drug treatment for patients in the E2007 treatment group will be started 2 mg E2007 o.d. but will be escalated to 4 mg E2007 o.d. after three weeks.

NCT ID: NCT00393562 Withdrawn - Parkinson's Disease Clinical Trials

Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease

Start date: March 2006
Phase: N/A
Study type: Interventional

This is an open-label cross-over randomized control study comparing the effect of modafinil and methylphenidate in patients with Parkinson's disease with excessive daytime sleepiness.